

Special Issue

Advanced Research in Lysosomal Storage Disorders

Message from the Guest Editors

Lysosomal diseases (LDs) are a group of about 70 hereditary metabolic disorders caused by the inactivation of one of the genes encoding components of lysosomal machinery. LDs are rare diseases (combined incidence of about 1:5500) with mainly recessive inheritance. This Special Issue of *Biomedicines* will showcase novel developments in the field, presenting the state of the art on the screening, diagnosis, pathophysiology, and treatment of lysosomal diseases from all points of view (clinical, biochemical, genomic, and biomarkers) and will highlight questions that need to be addressed in the field.

Guest Editors

Dr. Francisco J. del Castillo

1. Servicio de Genética, Hospital Universitario Ramón y Cajal - IRYCIS, Madrid, Spain
2. Unit 728, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain

Prof. Dr. Enrique J. Calderón

Departamento de Medicina, Instituto de Biomedicina de Sevilla, CIBERESP, Hospital Universitario Virgen del Rocío, Facultad de Medicina, Universidad de Sevilla, Sevilla, Spain

Deadline for manuscript submissions

closed (30 April 2024)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



mdpi.com/si/109383

Biomedicines

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 5.2
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.3 days after submission; acceptance to publication is undertaken in 3.4 days (median values for papers published in this journal in the first half of 2024).